Drug Access News Today

/PRNewswire/ -- RazorMetrics, a healthcare technology company focused on lowering drug costs for health plans and self-funded employers, released their annual...

A government-appointed panel is considering allowing commonly used cough and cold medicines, antacids, and fever-reducing drugs to be sold over the counter (OTC) at general stores in India. While countries like Britain, the US, and Australia have clear guidelines for OTC drug sale, India lacks such regulations. In 2022, India approved a new OTC drug policy, but it was not implemented.

Families with workplace health insurance may have missed out on $125,000 in earnings over the past 3 decades due to rising premiums; so far, there have been about 600 drug price hikes in January; experts worry that minority and low-income people will not have easy access to zuranolone, the first FDA-approved postpartum depression pill.

David Fajgenbaum, MD, MBA, MSc, cofounder of Every Cure, shared that the organization is able to reduce clinical trial costs to $1 to $5 million per drug trial, and that clinical trials are not always necessary to expand a drug's indication.

NCPA presented at a health seminar on “Prescription Drug Access and Costs,” hosted by the National Conference of State Legislatures in Chicago and attended by state legislators with health care and insurance committee responsibilities. (NCSL maintains a database of prescription drug state bills that you might be interested to browse.) NCPA’s presentation focused on PBM vertical integration and the need for state anti-patient steering legislation.

Multinational pharmaceutical company Johnson & Johnson (J&J) has announced that it will not enforce secondary patents for its anti-TB drug Bedaquiline in low and middle income countries. This means that Indian pharmaceutical companies will be able to supply generic versions of the drug without the fear of litigation.

/PRNewswire/ -- Cure®, a healthcare innovation campus in New York City, will open and host key events of the Science Summit at the 78th United Nations General...

Care quality is high in both the United States and Canada, but there are commonalities in regard to drug access and cost issues, particularly with advanced medications, noted G. B. John Mancini, MD, University of British Columbia.

Just 12% of some 162,000 people estimated to have cystic fibrosis (CF) are getting Vertex’s pricey triple-combination therapy Trikafta, the Journal of Cystic Fibrosis reports. Still, that figure may be low given the drug’s myriad reimbursement deals last year, plus a pair of recent approval to treat CF in kids younger than 12.

When Novartis reported first-half Zolgensma sales a few months ago, the company said its spinal muscular atrophy gene therapy was growing thanks to "expanding access" in Europe. This week at the Fierce Biotech Cell & Gene Therapy event, an exec outlined what's driving the uptake.